DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma
September 20, 2024 07:40 ET
|
Janssen Cilag International NV
Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed 60 percent reduction in risk...
3D Printing Market expected to reach USD 118.9 Billion by 2032 | Transformative Technologies and Expanding Applications Drive Future Prospects | Research by SNS Insider
September 17, 2024 09:00 ET
|
SNS Insider pvt ltd
Pune, Sept. 17, 2024 (GLOBE NEWSWIRE) -- 3D Printing Market Size Analysis: “According to SNS Insider, the 3D Printing Market Size was USD 21.1 Billion in 2023 and is projected to reach USD 118.9...
3D Printing Medical Devices Global Markets Report 2024-2029 Featuring 3D Systems, Carbon, Cellink, Eos, Fabrx, Formlabs, GE, HP, Materialise, Nikon, Prodways, Proto Labs, Regenhu, Renishaw, Stratasys
September 17, 2024 07:10 ET
|
Research and Markets
Dublin, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The "3D Printing Medical Devices: Global Markets" report has been added to ResearchAndMarkets.com's offering.This report provides an overview of the...
Global Additive Manufacturing Industry Research 2024-2031: Use of AI in 3D Printing, On-Demand Spare Products Production, and Increased Product Customization
September 17, 2024 04:05 ET
|
Research and Markets
Dublin, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The "Global Additive Manufacturing Market Size, Share, Forecast, & Trends Analysis by Offering, Technology, End-user, and Geography - Forecast to 2031"...
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle invasive bladder cancer
September 16, 2024 03:09 ET
|
Janssen Cilag International NV
TAR-200 plus cetrelimab treatment results in tumour size reduction in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence1 BEERSE, BELGIUM ,...
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
September 15, 2024 02:37 ET
|
Janssen Cilag International NV
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive1 ...
RYBREVANT®▼ (amivantamab) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
September 14, 2024 10:00 ET
|
Janssen Cilag International NV
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease1 New results show potential of amivantamab beyond lung cancer1 BEERSE,...
RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
September 14, 2024 03:15 ET
|
Janssen Cilag International NV
Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE, BELGIUM , Sept. 14, 2024 (GLOBE NEWSWIRE) --...
Prophylactic dexamethasone regimen reduces infusion-related reactions in patients with EGFR-mutated advanced non-small cell lung cancer treated with intravenous RYBREVANT®▼ (amivantamab)
September 10, 2024 18:20 ET
|
Janssen Cilag International NV
The 8 mg pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous amivantamab, a three-fold reduction from 67.4 percent historically seen with standard IRR...
Industrial 3D Printing Market to hit $88 Bn by 2032, Says Global Market Insights Inc.
September 03, 2024 05:25 ET
|
Global Market Insights Inc.
Selbyville, Delaware,, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The industrial 3d printing market is predicted to hit USD 88 Billion by 2032, as reported in a research study by Global Market Insights...